See more : Research Alliance Corp. II (RACB) Income Statement Analysis – Financial Results
Complete financial analysis of ChemoCentryx, Inc. (CCXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChemoCentryx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aspen Digital Inc (ASPD) Income Statement Analysis – Financial Results
- Choksi Imaging Limited (CHOKSI.BO) Income Statement Analysis – Financial Results
- Qt Group Oyj (QTGPF) Income Statement Analysis – Financial Results
- Precious Dragon Technology Holdings Limited (1861.HK) Income Statement Analysis – Financial Results
- Saturn Oil & Gas Inc. (SOIL.TO) Income Statement Analysis – Financial Results
ChemoCentryx, Inc. (CCXI)
About ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.22M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Cost of Revenue | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 31.92M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Gross Profit Ratio | 99.06% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 82.99M | 77.88M | 70.28M | 62.74M | 49.50M | 37.95M | 33.18M | 33.82M | 33.54M | 34.57M | 28.36M | 33.53M | 27.47M | 35.06M |
| General & Administrative | 0.00 | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.85M | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Other Expenses | 302.00K | 0.00 | -176.00K | 0.00 | 0.00 | -500.00K | 0.00 | 0.00 | 27.48M | 29.15M | 0.00 | 0.00 | 0.00 | -536.00K |
| Operating Expenses | 162.14M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Cost & Expenses | 162.45M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Interest Income | 859.00K | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 402.00K | 436.00K | 297.00K | 1.76M |
| Interest Expense | -2.70M | 2.64M | 2.15M | 1.22M | 4.00K | 0.00 | 0.00 | 24.00K | 59.00K | 794.00K | 734.00K | 81.00K | 76.00K | 129.00K |
| Depreciation & Amortization | 3.14M | 797.00K | 1.64M | 512.00K | 418.00K | 348.00K | 477.00K | 543.00K | 576.00K | 592.00K | 754.00K | 660.00K | 713.00K | 707.00K |
| EBITDA | -131.31M | -51.92M | -51.70M | -36.23M | 18.28M | -39.62M | -46.83M | -46.36M | -38.04M | -38.51M | -3.13M | -2.43M | 16.71M | -17.66M |
| EBITDA Ratio | -407.49% | -80.00% | -143.80% | -84.50% | 22.16% | -346.44% | 0.00% | 0.00% | -627.69% | -710.56% | -9.88% | -6.96% | 33.58% | -74.97% |
| Operating Income | -134.45M | -55.18M | -58.30M | -40.27M | 16.49M | -40.72M | -47.69M | -47.40M | -39.12M | -39.63M | -4.30M | -5.96M | 15.70M | -20.13M |
| Operating Income Ratio | -417.24% | -85.03% | -162.17% | -93.92% | 19.99% | -356.10% | 0.00% | 0.00% | -645.46% | -731.32% | -13.58% | -17.09% | 31.55% | -85.46% |
| Total Other Income/Expenses | -1.84M | -179.00K | 2.81M | 2.30M | 1.37M | 757.00K | 384.00K | 470.00K | 442.00K | -261.00K | -316.00K | 2.79M | 221.00K | 1.63M |
| Income Before Tax | -131.76M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.17M | 15.92M | -18.49M |
| Income Before Tax Ratio | -408.87% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -9.09% | 32.00% | -78.52% |
| Income Tax Expense | -2.70M | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 418.00K | -73.00K | 293.00K | -23.00K |
| Net Income | -129.06M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.10M | 15.62M | -18.47M |
| Net Income Ratio | -400.51% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -8.88% | 31.41% | -78.43% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 | 0.37 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| Weighted Avg Shares Out | 65.69M | 65.69M | 56.90M | 49.81M | 48.41M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
| Weighted Avg Shares Out (Dil) | 65.69M | 65.69M | 56.90M | 49.81M | 49.62M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
ChemoCentryx Announces Changes to its Board of Directors
-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board --
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:...
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at...
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan),...
ChemoCentryx: A Biotech Stock Well Worth the Risk
In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point for a stock that had been in a sharp downturn...
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Why ChemoCentryx Shares Are Popping Off
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported quarterly losses of 55 cents per share which missed the analyst consensus estimate of a loss of 30 cents.
ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2022 Results - Earnings Call Transcript
ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, President and Chief Executive Officer Tausif Butt – Executive Vice President, Chief Operating Officer Susan Kanaya – Executive...
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a...
Source: https://incomestatements.info
Category: Stock Reports